Search in the Abstract Database

Search Abstracts 2016

* = Presenting author

P046 Therapeutic effects of mouse bone marrow–derived single clonal mesenchymal stem cells in a mouse model of inflammatory bowel disease

K. B. Hahm*1, S. U. Song2, S. H. Park3

1CHA University, Gastroenterology, Seongnam, South Korea, 2Inha University, Gastroenterology, Incheon, South Korea, 3Sungkyunkwan University, Ciological Science, Suwon, South Korea

Background

Mouse bone marrow–derived clonal mesenchymal stem cells (mcMSCs), characterised with stem cells possessing multilineage differentiation potential and high regenerative capability, but originated from a single cell by a subfractionation culturing method, are recognised as a new paradigm for stem cell therapy owing to the homogenous cell population.

Methods

Next to proven therapeutic effects against experimental pancreatitis, in the current study, we demonstrated that mcMSCs showed significant therapeutic effects in dextran sulfate sodium (DSS)–induced experimental colitis model supported with anti-inflammatory and restorative activities

Results

mcMSCs significantly reduced the disease activity index (DAI) score, including weight loss, stool consistency, and intestinal bleeding and significantly increased survival rates (p < 0.01). The pathological scores were also significantly improved with mcMSC 
(p < 0.0001). We have demonstrated that especial mucosal regeneration activity accompanied with significantly lowered level of apoptosis as beneficiary actions of mcMSCs (p < 0.001) in UC models. The levels of inflammatory cytokines including TNF-α, IFN-γ, IL-1β, IL-6, and IL-17 were all significantly concurrent with significantly repressed NF-☐B activation compared with the control group (p < 0.01), and significantly decreased infiltrations of responsible macrophages and neutrophils (p < 0.05).

Conclusion

mcMSCs are applicable as a potential source of cell-based therapy in inflammatory bowel diseases, especially contributing either to prevent relapse or to accelerate healing as solution to unmet medical needs in IBD therapy.